Home › Funds › Guardian Variable Products Trust › Guardian Small-Mid Cap Core VIP Fund
Fund family: Guardian Variable Products Trust · Filed by Guardian Variable Products Trust (CIK 1668512) · SEC series S000068792
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 718 with, 4 against, 12 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 3 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Guardian Variable Products Trust’s manager page (18,796 ballot items across 19 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Guardian Variable Products Trust | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 93.4% | 711 | 95.0% | 16,463 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 8.5% | 505 |
Each ballot item this fund voted is set against the votes of the other Guardian Variable Products Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Guardian Variable Products Trust funds on 2 items (3.8% of the 52 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Guardian Variable Products Trust funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORPORATION | 2026-06-26 | Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan. | Against | FOR — 3 of 3 Guardian Variable Products Trust funds | Against | Passed (calculated), 72.0% support |
| OKTA, INC. | 2026-06-18 | To approve, on an advisory non-binding basis, the compensation of our named executive officers. | Against | FOR — 2 of 3 Guardian Variable Products Trust funds | Against | Approved, 75.9% support |
Download all 2 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 95.4% of this fund’s 734 such votes could be given a sector; the other 34 (4.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Finance | 173 | 1 | 0.6% |
| Industrials | 146 | 1 | 0.7% |
| Health Care | 124 | 1 | 0.8% |
| Consumer Discretionary | 122 | 0 | 0.0% |
| Technology | 46 | 0 | 0.0% |
| Real Estate | 26 | 0 | 0.0% |
| Utilities | 24 | 0 | 0.0% |
| Basic Materials | 17 | 0 | 0.0% |
| Energy | 17 | 0 | 0.0% |
| Telecommunications | 5 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 521 | 0 |
| Audit-related | 84 | 0 |
| Say-on-Pay | 84 | 0 |
| Compensation | 18 | 1 |
| Corporate Governance | 16 | 2 |
| Capital Structure | 9 | 0 |
| Other | 4 | 0 |
| Shareholder Rights and Defenses | 3 | 1 |
| Extraordinary Transactions | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| OKTA, INC. | June 18, 2026 | $6M | 5 | 0 |
| BIO-RAD LABORATORIES, INC. | April 21, 2026 | $5M | 6 | 1 |
| HAEMONETICS CORPORATION | July 24, 2025 | $5M | 11 | 0 |
| ON SEMICONDUCTOR CORPORATION | May 14, 2026 | $5M | 10 | 0 |
| ROKU, INC. | June 11, 2026 | $5M | 5 | 0 |
| AZENTA, INC. | January 28, 2026 | $5M | 13 | 0 |
| BRUKER CORPORATION | May 21, 2026 | $4M | 5 | 0 |
| ALLIENT INC. | May 6, 2026 | $4M | 8 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 21, 2026 | BIO-RAD LABORATORIES, INC. | Stockholder proposal regarding dual class capital structure. Shareholder proposal | For | Against |
| April 16, 2026 | HUMANA INC. | The stockholder proposal requesting shareholder approval requirement for excessive golden parachutes, if properly presented at the meeting. Shareholder proposal | For | Against |
| April 30, 2026 | CROWN HOLDINGS, INC. | Consideration of a Shareholder proposal regarding Shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 14, 2026 | CBOE GLOBAL MARKETS, INC. | Stockholder proposal regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
741 ballot items at 84 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Guardian Small-Mid Cap Core VIP Fund voted at 84 shareholder meetings of 84 companies, on 741 ballot items in all. Where management made a recommendation, the fund followed it on 97.8% of the items and voted against it 4 times. Its most frequent area of disagreement was corporate governance (2 of its votes against management). It voted on 5 shareholder proposals. It voted FOR the board's own proposals less often than Guardian Variable Products Trust's funds as a whole (93.4% against 95.0%). It voted differently from most Guardian Variable Products Trust funds on 2 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Guardian Variable Products Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.